Clinical Trial Detail

NCT ID NCT03072043
Title Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

acute myeloid leukemia

myelodysplastic/myeloproliferative neoplasm

myelodysplastic syndrome

Therapies

APR-246 + Azacitidine

Age Groups: senior adult

No variant requirements are available.